Quality of Life in Multiple Myeloma Patients Treated With Bortezomib

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This observational study will observe the degree of the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions). Both tools are validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma by analyzing factors that affect the quality of life.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• Patients who are newly prescribed bortezomib injection as a secondary agent for the treatment of multiple myeloma

• Patients who can understand and fill out quality of life questionnaires, and who agree to provide information will be included

Exclusion Criteria:

• Patients who are hypersensitive to the bortezomib or any component of bortezomib or with a history of the hypersensitivity

• Patients with severe hepatic impairment

• Pregnant women